Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) Sees Significant Growth in Short Interest

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) saw a large growth in short interest during the month of October. As of October 30th, there was short interest totaling 1,324 shares, a growth of 586.0% from the October 15th total of 193 shares. Based on an average daily volume of 8,514 shares, the short-interest ratio is presently 0.2 days. Currently, 0.0% of the company’s shares are sold short.

Oaktree Acquisition Corp. III Life Sciences Trading Up 0.1%

Shares of OACC opened at $10.71 on Friday. The stock has a fifty day moving average of $10.74 and a two-hundred day moving average of $10.70. Oaktree Acquisition Corp. III Life Sciences has a fifty-two week low of $10.50 and a fifty-two week high of $10.93.

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) last posted its quarterly earnings data on Wednesday, August 12th. The company reported $0.07 earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Oaktree Acquisition Corp. III Life Sciences

Several institutional investors have recently added to or reduced their stakes in the business. Periscope Capital Inc. purchased a new position in Oaktree Acquisition Corp. III Life Sciences during the third quarter worth about $3,488,000. Rangeley Capital LLC boosted its stake in Oaktree Acquisition Corp. III Life Sciences by 52.8% in the 1st quarter. Rangeley Capital LLC now owns 61,188 shares of the company’s stock worth $647,000 after buying an additional 21,156 shares during the last quarter. Finally, DLD Asset Management LP grew its holdings in Oaktree Acquisition Corp. III Life Sciences by 0.9% in the 1st quarter. DLD Asset Management LP now owns 136,735 shares of the company’s stock valued at $1,447,000 after buying an additional 1,200 shares during the period.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of Oaktree Acquisition Corp. III Life Sciences from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, October 2nd. One analyst has rated the stock with a Hold rating. Based on data from MarketBeat, Oaktree Acquisition Corp. III Life Sciences presently has a consensus rating of “Hold”.

About Oaktree Acquisition Corp. III Life Sciences

Oaktree Acquisition Corp. III Life Sciences is a special purpose acquisition company (SPAC) formed to pursue a business combination with a company in the life sciences sector. Its potential transactions could include a merger, acquisition, or similar combination. The company was sponsored by Oaktree Capital Management. As a SPAC, it did not have its own operating business or sell products and services; its intended role was to identify and combine with a business in its target sector.